https://scholars.lib.ntu.edu.tw/handle/123456789/465746
標題: | 111in-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma | 作者: | Shih Y.-H. Peng C.-L. Lee S.-Y. Chiang P.-F. Yao C.-J. Lin W.-J. Luo T.-Y. MING-JIUM SHIEH |
公開日期: | 2015 | 出版社: | Impact Journals LLC | 卷: | 6 | 期: | 18 | 起(迄)頁: | 16601-16610 | 來源出版物: | Oncotarget | 摘要: | Colorectal adenocarcinoma is a common cause death cancer in the whole world. The aim of this study is to define the 111In-cetuximab as a diagnosis tracer of human colorectal adenocarcinoma. In this research, cell uptake, nano-SPECT/CT scintigraphy, autoradiography, biodistribution and immunohitochemical staining of EGF receptor were included. HCT-116 and HT-29 cell expressed a relatively high and moderate level of EGF receptor, respectively. The nano-SPECT/CT image of 111In-cetuximab showed tumor radiation uptake of subcutaneous HCT-116 xenograft tumor was higher than SW-620. Autoradiography image also showed that tumor of HCT-116 had high 111In-cetuximab uptake. Mice that bearing CT-26 in situ xenograft colorectal tumors showed similar high uptake in vivo and ex vivo through nano-SPECT/CT imaging at 72 hours. Metastatic HCT-116/Luc tumors demonstrated the highest uptake at 72 hours after the injection of 111In-cetuximab. Relatively, results of 111In-DTPA showed that metabolism through urinary system, especially in the kidney. The quantitative analysis of biodistribution showed count value of metastatic HCT-116/Luc tumors that treated with 111In-cetuximab had a significant difference (P < 0.05) compared with that treated with 111In-DTPA after injection 72 hours. Result of immunohistologic staining of EGF receptor also showed high EGF receptor expression and uptake in metastatic colorectal tumors. In summary, we suggested that 111In-cetuximab will be a potential tool for detecting EGF receptor expression in human metastatic colorectal carcinoma. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937868362&doi=10.18632%2foncotarget.3968&partnerID=40&md5=7b4662e8e9f186944d4672179ed9f78b https://scholars.lib.ntu.edu.tw/handle/123456789/465746 |
ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.3968 | SDG/關鍵字: | cetuximab in 111; epidermal growth factor receptor; pentetate indium in 111; radiopharmaceutical agent; unclassified drug; antineoplastic agent; cetuximab; EGFR protein, human; epidermal growth factor receptor; indium; animal experiment; animal model; animal tissue; Article; autoradiography; colorectal carcinoma; computer assisted scintigraphy; controlled study; CT-SPECT scanner; drug distribution; drug metabolism; ex vivo study; human; human cell; in vivo study; kidney; mouse; nonhuman; protein expression; protein targeting; single photon emission computer tomography; tumor xenograft; urinary tract; adenocarcinoma; animal; cancer transplantation; Colorectal Neoplasms; diagnostic imaging; HCT 116 cell line; HT-29 cell line; metabolism; metastasis; nude mouse; physiology; radiography; single photon emission computed tomography; transport at the cellular level; tumor cell line; xenograft; Adenocarcinoma; Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; HCT116 Cells; Heterografts; HT29 Cells; Humans; Indium Radioisotopes; Kidney; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Radiography; Receptor, Epidermal Growth Factor; Tomography, Emission-Computed, Single-Photon |
顯示於: | 醫學工程學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。